Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting

Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to invest in. Geron Corporation (NASDAQ:GERN) announced on December 8 that new data was presented at the 67th American Society of Hematology (ASH) 2025 Annual Meeting at Orlando, Florida, with the poster and oral presentations collectively adding to the evidence supporting RYTELO’s potential across lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF). RYTELO (imetelstat) is Geron Corporation’s (NASDAQ:GERN) first-in-class telomerase inhibitor.

Management stated that the new data provides additional insights into the working of imetelstat and shows its potential long-term benefit as a differentiated treatment option for eligible patients with lower-risk MDS. In addition, the oral presentation from pooled analyses of the IMerge population shows that treatment-emergent cytopenias may reflect on-target effects linked to meaningful clinical outcomes, which include transfusion independence and hemoglobin increases in lower-risk MDS. Additional analyses in myelofibrosis and advanced MDS/AML also provide significant context for gaining insight into the biology of telomerase inhibition.

Geron Corporation (NASDAQ:GERN) added that additional poster presentations offered long-term outcomes data, which includes exploratory biomarker analyses in MF, survival data in LR-MDS, and ongoing combination and investigator-sponsored studies spanning the myeloid malignancy spectrum.

Geron Corporation (NASDAQ:GERN) is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.